Hematopoiesis, the process by which mature blood cells arise, is controlled by multiple transcription factors, which act in stage-and lineage-specific complexes. It is a major goal to elucidate the genes regulated by these transcription factors, in order to obtain a full understanding of the process and its malignant counterpart, leukemia. Myb family transcription factors play a central role in hematopoiesis. To identify new Myb family target genes, we have used an inducible dominant-negative protein for a subtraction cloning protocol in a model cell system (FDCP-Mix) with many characteristics of normal hematopoiesis. We present here a novel group of 29 validated Myb family target genes of diverse functions.
Introduction
The c-myb gene is the cellular counterpart of an oncogene transduced by the avian myeloblastosis virus (Klempnauer et al., 1983) . c-Myb plays a pivotal role during hematopoiesis: analysis of mice lacking the c-myb gene shows that it is absolutely required for adult hematopoiesis (Mucenski et al., 1991; Clarke et al., 2000; Sumner et al., 2000; Emambokus et al., 2003) . These data support and extend results derived from experiments using tissue culture model systems, which suggest that c-Myb is involved in maintaining hematopoietic cells in an immature state. For example, inhibition of c-Myb activity using conditionally active constructs provides a stimulus to hematopoietic differentiation (Hogg et al., 1997; White and Weston, 2000) , and conversely, forced expression of c-Myb in myeloid and erythroid cell lines inhibits terminal differentiation (McMahon et al., 1988; Selvakumaran et al., 1992; . Similar inhibitory effects on differentiation have been reported for the related B-myb protein (Bies et al., 1996) .
Myb proteins are DNA binding transcription factors, but despite the efforts of many investigators over more than two decades, we still have little idea how the effects of Myb proteins are mediated. The answer to this problem lies at least in part in finding out what target genes Myb proteins are able to directly regulate. The field has suffered for many years from a dearth of known targets, but this has now been remedied, by a combination of old-fashioned methods such as subtraction cloning and differential display (e.g. see Bartley et al., 2001) , and more recently, by microarray analysis (Rushton et al., 2003) . In respect of the role of Myb proteins in maintaining the immature hematopoietic phenotype, little is known regarding relevant target genes, although the c-kit proto-oncogene is noteworthy (Vandenbark et al., 1996; Hogg et al., 1997; Ratajczak et al., 1998) .
In pursuit of further Myb family target genes, we developed an inducible dominant-negative Myb molecule, MERT, which is able to inhibit the activity of all three Myb family members. MERT comprises the DNA binding domain of c-Myb fused to the Drosophila Engrailed repressor domain and a mutated version of the estrogen receptor hormone binding domain inducible only by 4-hydroxy tamoxifen (4OHT). In the presence of 4OHT, MERT becomes active, and is able rapidly and specifically to repress endogenous Mybregulated transcription (Taylor et al., 1996) . To investigate the function of Myb proteins during early hematopoiesis, we previously generated MERT-expressing clones of the multipotent hematopoietic progenitor cell line FDCP-Mix clone A4. MERT induction resulted in inhibition of self-renewal in the A4 cells, and forced apoptosis and differentiation. Differentiation was to granulocytes and monocyte/macrophages and closely associated with a G1-S phase block in the cell cycle. Cytokine-induced differentiation in the MERT clones was also affected, with proliferation and survival both reduced (White and Weston, 2000) . We have now used this system to perform a subtraction screen for Mybregulated genes, and report here the identification of 29 new targets, validated by a combination of mRNA expression studies and c-and B-Myb-specific promoterdirected chromatin immunoprecipitation. To investigate the cell type specificity of the Myb target genes, we also examined their expression in activated T cells from mice expressing a lymphoid-specific MEnT transgene, which is a constitutively active version of MERT (Badiani et al., 1994) , and found that relative to wild-type controls, 24 of the targets were downregulated. These data suggest that some of the target genes we have defined may be regulated by Myb proteins in multiple cell types.
Results

Isolation of Myb-regulated genes by subtraction cloning
To establish a system in which transcription regulated by Myb family proteins could be rapidly switched on and off, an inducible dominant-negative Myb protein, MERT, was stably expressed in the multipotent hematopoietic cell line FDCP-mix (White and Weston, 2000) . When 4OHT was added to MERT-expressing cells, mRNA levels of the known Myb regulated gene bcl-2 decreased relatively slowly, with maximal effects requiring over 24 h of treatment (data not shown). In order to bias our experiment towards cloning direct Myb family targets, we therefore decided to concentrate on mRNAs re-expressed at early times following 4OHT removal, rather than mRNAs lost following 4OHT addition. Using this system, no increases were observed in levels of endogenous B-or c-Myb mRNAs upon 4OHT withdrawal (data not shown), so effects seen are related to regulation of the exogenous MERT. To define a suitable time, mRNA levels of the Myb-regulated gene bcl-2 were measured after 2, 5 and 8 h following removal of 4OHT (Figure 1) . After 5 h, bcl-2 mRNA levels were significantly increased, and so we chose 5 h as the reexpression time point.
For subtraction cloning, MERT expressing FDCPmix cells were cultured for 3 days with 300 nM 4OHT.
RNA was harvested from half the cells for the driver sample and the other half were resuspended in medium lacking 4OHT, cultured for 5 h and then harvested for the tester sample. The same procedure was performed for control cells, expressing the ERT protein, which is the same as MERT except that it cannot bind DNA (White and Weston, 2000) . A subtracted library was produced from MERT cells, which was then differentially screened by hybridization with control subtracted libraries to eliminate false positives. This revealed that of 149 clones analysed which contained cDNA inserts, 121 were not present in the control libraries. In all, 70 of these 121 clones hybridized strongly to the MERT subtracted library. Following sequencing of the 70 clones, we excluded those encoding endogenous retroviral sequences and those from the mitochondrial genome (five clones total). The remainder were checked for MERT-induced changes in expression by a combination of Northern blotting and RNAse protection assay (22 clones; data not shown), and semiquantitative RT-PCR (all clones). To eliminate false positives and to control for MERT FDCP-Mix clone-to-clone variation, semi-quantitative RT-PCR was performed multiple times on both MERT-FDCP-Mix mRNA samples from a cloned MERT cell line, and also from an independently transfected pool of G418- 
Analysis of Myb binding sites in target gene promoters
Although the short time of MERT deinduction was expected to have biased our selection of genes towards those directly regulated by Myb proteins, we could not exclude the possibility that some of the targets might be indirect. Analysis of the 5 0 flanking regions of those target genes whose mRNA start sites have been mapped onto the mouse genome sequence showed that all contained Myb binding sites (MBSs ; Table 1 ), and so we chose to look at direct binding of individual Myb family members to a selection of these sites by chromatin immunoprecipitation (ChIP). Where more than one MBS existed, we chose the site nearest the likely mRNA start for initial analysis. ChIP was performed in parental FDCP-Mix cells using antibodies to A-, B-and c-Myb proteins. FDCP-Mix cells do not express A-Myb protein (G.L., unpublished) and as expected no PCR product above background was ever observed with anti-A-Myb ChIP. Representative ChIP results are shown in Figure 3 and Table 2 summarizes the results for the target genes tested. As can be seen in Figure 3 , binding to some of the sites was quite weak, but all data were consistently reproducible, implying that the interaction was real. We detected an MBS specificity for either c-Myb or B-Myb for sites in the 5) . An RNase protection assay was performed to simultaneously measure mRNA levels of bcl2 and GAPDH Cbx4, Hspa8, Lca and Mad1l1 upstream regions; however, further binding sites from these upstream regions bound both B-and c-Myb. In all, we tested 26 potential binding sites from the 5 0 proximal regions of 14 novel target genes. A total of 18 sites could be immunoprecipitated with antibodies against both B-and c-Myb, 1 site appeared to be B-Myb specific, and four sites were c-Myb specific. A total of 12/14 target genes tested had 5 0 proximal regions containing Myb sites occupied in vivo by Myb proteins. We also performed ChIP of the well-characterised Myb binding site in the murine Bcl2 promoter (Frampton et al., 1996; Taylor et al., 1996) , and found that in FDCP-Mix cells, c-Myb but not B-Myb appears to be bound (Figure 3) .
To find out whether the genomic regions we identified by ChIP shared any transcription factor binding sites apart from the MBS, we looked for motifs in the 50 bp either side of the MBS using the MatInspector program (Quandt et al., 1995) . Table 3 shows the MBSs and flanking sequences, with those MBSs binding either Bor c-Myb specifically shown below the rest. For Ppp3ca, both sites in the promoter are shown for completeness, but we could not differentiate whether both or just one bound Myb protein as they were too close together to separate by ChIP. This was also the case with Lca sites 2 and 3. Although no common motifs were evident, these sites do provide a useful reference set as few bona fide MBSs are currently in the literature.
Target gene regulation in distinct tissue types
One of the potential Myb family target genes we isolated encodes the tetraspanin receptor Cd53, which is expressed on the surface of both myeloid and T cells, and has some antiapoptotic properties (Yunta and Lazo, 2003) . Its expression pattern was of interest, as c-Myb has multiple roles during thymopoiesis (Taylor et al., 1996; Allen et al., 1999; Bender et al., 2004) , and has also been shown to affect the activation of mature peripheral T cells (Badiani et al., 1994; Taylor et al., 1996) , where it is a downstream effector of IL2 receptor signalling (Lauder et al., 2001) . We showed by Northern blotting in MERT FDCP-Mix cells that Cd53 mRNA was induced strongly upon 4OHT washout (Figure 4a ). To determine whether this gene might also be regulated by Myb proteins in T cells, we investigated its expression in MEnT transgenic mice, in which a constitutive version of MERT, termed MEnT, is expressed in the T-cell lineage from early times (Badiani et al., 1994) . Cd53 expression, as monitored by flow cytometry, was significantly downregulated in MEnT thymocytes (Figure 4b ; darker lines), relative to wild-type (WT) thymocytes (Figure 4b ; lighter lines), with CD8 þ single positive (SP) cells apparently more affected than their CD4 þ SP counterparts. To determine whether expression of the other target genes we had isolated was also modified in MEnT T cells, we decided to look at expression in mature peripheral CD4
þ SP T cells purified from the spleens of either MEnT or WT animals. cDNA was made either from naı¨ve CD4 þ SP cells, or from CD4 þ SP cells which had been activated in vitro by crosslinking to a-CD3 and a-CD28 antibodies, and then purified on the basis of expression of the activation marker CD25. Results for naı¨ve CD4
þ SP cells are shown in Figure 5 , lanes 1 (WT) and 2 (MEnT) and for activated CD4 þ SP cells in Figure 5 lanes 3 (WT) and 4 (MEnT). A summary of the data is presented in Table 2 . One gene (Lca) was not expressed in activated CD4 þ SP cells, two of the unassigned cDNAs were not regulated, and two genes (Emi2 and Tcfec) appeared reverse-regulated upon activation. However, the remaining 24 genes were downregulated in MEnT T cells relative to WT controls. Although it would clearly be premature to state that the genes are direct Myb targets in T cells, these data strongly suggest that manipulation of Myb activity in two very different cell types, FDCP-Mix and primary T cells, results in common regulation of most of the Myb family targets we have found.
Discussion
We have identified 29 new Myb family target genes in the hematopoietic progenitor cell line FDCP-Mix, and have shown that the majority of these genes are also regulated in a transgenic mouse model in which Myb protein activity is inhibited in primary T cells. Our data validating these genes as Myb family targets are summarized in Table 2 . From our ChIP experiments, it is likely that most of the target genes responding to MERT and MEnT can be regulated by both B-and c-Myb, and that therefore MERT and MEnT act as pan-specific inhibitors of Myb protein activity.
By ChIP analysis on a number of the upstream regions of the validated target genes, we have shown that, as has previously been inferred (Lei et al., 2004) , there appears to be some specificity with regard to which Myb family member is able to bind to particular Myb sites in chromatin; five out of the 23 sites we were able to show bound Myb in vivo were exclusively associated with either B-Myb (one site) or c-Myb (four sites). The functional reason for this is unclear, as with the exception of the Bcl2 gene, all these sites occurred in upstream regions in which both B-and c-Myb were able to bind other sites. Further studies to map which MBSs are required for the in vivo activity of these promoters are required to resolve this question. It is also not evident what the structural basis for these differences might be. In vitro studies of the DNA binding properties of purified Myb family proteins have demonstrated that all three proteins have the same minimal binding consensus YAAC G / T G but that B-Myb binds more weakly than A-or c-Myb to YAACTG (Howe and Watson, 1991; Bergholtz et al., 2001) . Of the sites we found here which bound both B-and c-Myb, most (14/18) were of the YAACTG type; the four sites binding c-Myb alone were no different to those binding both B-and c-Myb, and the one site which appeared to bind B-Myb and not c-Myb had the sequence TAACTG. This discrepancy underlines the difficulty of predicting binding site specificity in nonchromatinized DNA. Potential explanations for specificity are that off-DNA interactions with other components of the transcriptional regulatory machinery are responsible Golgi/ER and trafficking Bet1l Copa Lca Sec31l1
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Myb family target genes G Lang et al (reviewed in Ness, 2003) , and/or that the individual Myb transcriptional activation domains might impart some specificity (Lei et al., 2004) . It is also likely that B-and c-Myb are differentially regulated both transcriptionally and post-transcriptionally, such that their levels and binding affinity for DNA vary according to the cell cycle and differentiation status of a cell.
The new Myb target genes are a functionally diverse group (see Table 4 ), and divide into those which may play a part in known Myb-regulated pathways, and those suggesting hitherto unsuspected aspects of cellular control in which Myb proteins may be important. Myb proteins have previously been implicated as regulators of apoptosis in both normal and cancerous cells (reviewed in Weston, 1998) , and so it is pleasing that four of the new targets are involved in protecting from apoptosis and that three of these also have links to cancer. Api5 (AAC-11) was cloned as a gene inhibiting apoptosis following growth-factor withdrawal (Tewari et al., 1997) , and has also been shown to act as a prognostic marker in non-small-cell lung cancer (Sasaki et al., 2001) . Crosslinking of the tetraspanin receptor Cd53, which is normally involved in lymphocyte activation (Lagaudriere-Gesbert et al., 1997), prevents cell death in a model of lymphoma (Yunta and Lazo, 2003) . Birc3 (c-IAP2) is an intriguing target as it is a very well-characterized suppressor of cell death (reviewed in Salvesen and Duckett, 2002) , able to induce antiapoptotic NFkB (Chu et al., 1997) , directly inhibit caspases (Deveraux et al., 1998) and neutralize its own inhibitor, the mitochondrial death-inducing factor Smac/Diablo (Wilkinson et al., 2004) . The final antiapoptotic gene, the Set oncogene, was originally cloned as a breakpoint translocation from an acute leukemia (Adachi et al., 1994) , and its protein product is a key suppressor of NM23H1, the DNAase initiating granzyme-A-mediated apoptosis (Fan et al., 2003) . It is also thought to play a role in inhibition of transcription, as part of the INHAT complex (see below). The other apoptosis-associated Myb protein target, Casp6, is part of the caspase cascade leading to cell death in many cell types, and its regulation by Myb lends credence to reports that under some circumstances, both B-and cMyb overexpression might cause, rather than prevent apoptosis Sala et al., 1996; Kumar et al., 2003) .
A second area in which both B-and c-Myb have been implicated is in cell cycle control, and the identification of Mad1l1 is significant in this respect. Mad1l1, the mammalian homolog of yeast Mad1, is involved in G2/ M mitotic checkpoint control: Mad1 mutants result in chromosome instability and MAD1l1 has been found mutated in a number of cancers (Tsukasaki et al., 2001) . Despite its role at G2/M, the Mad1l promoter is active predominantly in G1, precisely when both B-and c-Myb have their highest activity (Iwanaga and Jeang, 2002) . The chaperonin Cct2 has also been reported to affect the G1/S transition via its regulation of cyclin E formation (Won et al., 1998) , and has recently been reported to be a modulator of p53-induced proliferation arrest (Berns et al., 2004) .
Of the novel functional groups, the 12 genes involved in Golgi/ER and membrane trafficking, chaperoning of unfolded proteins, mitochondrial function and solute transport across membranes indicate the importance of Myb proteins to the basic life of the cell. Two further groups of genes involved in cytoskeletal regulation and cell adhesion, and transcriptional control are of great interest in terms of how Myb proteins might regulate differentiation and also tumor progression.
Actinin-1 (Actn1), Iqgap1, Moesin (Msn) and Psd4 (Tic/EFA6B) are all involved in cytoskeletal regulation, a process which is clearly of great importance during both tumor invasion and hematopoietic differentiation, where it facilitates changes in morphology, cell migration and 'niche finding' (e.g., see Zhang et al., 2003) . Actinin-1 is an actin-binding protein concentrated in focal adhesion plaques or adherens junctions, and couples the catenin-E-cadherin core of these junctions to actin microfilaments (reviewed in Gumbiner, 2000) . It is also important in linking the integrins, which connect the cell to signals from the extracellular matrix, to the actin cytoskeleton (reviewed in Mizejewski, 1999) . Moesin is involved in attachment of cortical actin microfilaments to the plasma membrane, and modulates the local rigidity of a cell, allowing rapid reorganization of the cytoskeleton and integral membrane proteins in response to extracellular signalling (reviewed in Gautreau et al., 2002) . The cytohesin family member Psd4 is a guanine nucleotide exchange factor, which acts on ARF6, a member of the Ras family of small GTPbinding protein. It is involved in actin cytoskeletal reorganization and membrane recycling and colocalizes with ARF6 in actin-rich membrane ruffles and microvilli-like protrusions (Derrien et al., 2002) . Finally, Iqgap1 is a central coordinator of signalling networks that are integral to maintaining cytoskeletal architecture and cell-cell adhesion ; it is overexpressed in a number of tumors (Nabeshima et al., 2002) and this overexpression has been reported to promote cell motility and tumor invasion (Mataraza et al., 2003) .
Four transcriptional regulators were identified as Myb protein targets. Tfb1m is a mitochondrial transcription factor required for mtDNA gene expression (Rantanen et al., 2003) , and Tcfec a bHLH-Zip factor of the Mitf-Tfe family (Steingrimsson et al., 2002) . As mentioned above, the Set oncoprotein has been purified as a component of the INHAT complex, which binds histones and blocks their acetylation, hence repressing transcription (Seo et al., 2001) . Similarly, Cbx4 (Pc2) is also a transcription repressor. It is a member of the Polycomb (PcG) family, and is involved in the stable repression of gene activation via its recruitment and sumoylation of the corepressor CtBP in PcG bodies (Kagey et al., 2003) . The activation by Myb proteins of Set and Cbx4 is intriguing for their regulation of the differentiation process, as establishment of lineage specificity is thought to require the stable transcriptional repression of pathways able to promote alternate lineage fate (reviewed in Orkin, 2003) .
The final Myb family target gene identified is Ppp3ca, which encodes the a isoform of calcineurin catalytic subunit A. Calcineurin is a calcium-calmodulin-activated serine-threonine phosphatase and is an important regulator of calcium-activated intracellular responses. It is a component of signalling cascades governing the development and function of multiple tissue types, and is coupled to gene regulation by virtue of its ability to activate the nuclear factor of activated T cells (NFAT) transcription factor (reviewed in Aramburu et al., 2004) . Knockout mouse studies have shown that Ppp3ca is important for mature T-cell function (Chan et al., 2002) . The possibility that Myb proteins might be involved in upstream activation of NFAT is of interest particularly in terms of Myb's antiapoptotic effects during T-cell activation and subsequent activation-induced cell death (Lauder et al., 2001) .
Clearly, the new information regarding Myb-regulated genes we present here must be complemented with functional studies determining which of these downstream targets is of importance in the role of Myb proteins in proliferation, death and differentiation; current and future studies in the laboratory are focused upon further elucidation of the complex series of events triggered upon activation of Myb proteins.
Materials and methods
Subtraction cloning
MERT expressing FDCP-mix cells were cultured for 3 days with 300 nM 4OHT (Sigma). RNA was harvested from half the cells for driver; the other half was washed twice, resuspended in medium without 4OHT, cultured for 5 h and harvested for tester. The same was performed for control ERT (White and Weston, 2000) -expressing cells. Total RNA was isolated by RNazol B (Biogenesis) and PolyA RNA was isolated by oligo dT magnetic beads (Promega, PolyATtractIII). Subtracted cDNA mixtures were generated using Clontech's PCR-Select cDNA Subtraction Kit. The forward subtracted library (MERT; Myb on-Myb off) was ligated into pCRII blue/white vector (Invitrogen). Inserts from white colonies were PCR amplified using nested PCR primers, analysed on agarose gels, and dot blotted onto Nylon (Hybond-N, Amersham). Replicate filters were probed with forward, reverse (MERT; Myb off-Myb on) and ERT subtracted cDNA mixtures with the adapters removed by Rsa-I digestion and column purification (Qiagen, QIAquick for PCR), as described (Clontech's PCRSelect Differential Screening Kit). Inserts were cycle sequenced from QIAquick-purified PCR reactions as used for dot blotting using nested primer. Plasmid was prepared from the clones specific to the forward subtracted mix.
Validation of targets
Northern blotting and RNAase protection assays were as described (White and Weston, 2000) . For RT-PCR expression analysis of target genes, clone MERT6 (White and Weston, 2000) and a bulk culture of MERT-FDCP-Mix cells kept under G418 selection were cultured in 300 nM 4OHT for 72 h. Cells were then washed in PBS and resuspended in medium either containing or lacking 4OHT for a further 7 h. To control for any effects of 4OHT alone, parental FDCP-Mix cells were treated similarly. Total RNA was made from all these samples using RNAzol according to the manufacturer's instructions. Total cDNA was made using SuperScript II RnaseH-Reverse Transcriptase (Invitrogen) according to the manufacturer's instructions. cDNA was quantitated and checked for purity by spectrophotometry at 260/280 nm and reactions were normalized against RT-PCR of actin cDNA. All RT-PCRs were repeated multiple times using MERT6 cDNA and at least twice using cDNAs made from two separate RNA isolates from MERT-FDCP-Mix bulk cultures. Linearity of PCRs was confirmed by comparing samples taken at 15, 20, 25 and 30 cycles. Data shown are for 25 cycles. Details of primers and conditions used for RT-PCR are available on request.
Chromatin immunoprecipitation
FDCP-Mix clone A4 cells were cultured under conditions designed to promote self-renewal as described (White and Weston, 2000) . ChIP methods were modified from Boyd and Farnham (1999) . Protein was crosslinked to chromatin by adding 1% formaldehyde to 10 7 cells for 10 min with shaking at room temperature. The reaction was stopped by the addition of glycine 125 mM for 5 min with shaking at room temperature. Cells were pelleted and washed three times with ice-cold PBS. Cell pellets were resuspended in 2 ml lysis buffer (5 mM PIPES, 85 mM KCl, 0.5% Igepal, protease inhibitors (Roche), 1 mM PMSF) and incubated on ice for 10 min. Nuclei were resuspended in 2 ml nuclear lysis buffer (50 mM Tris pH 8.0, 10 mM EDTA, 1% SDS, protease inhibitors (Roche), 1 mM PMSF) and incubated on ice for 10 min. Chromatin with a size averaging 300 bp was produced by sonication using a Soniprep 150 (MSE). Debris was cleared by centrifugation and the chromatin was diluted fivefold into ChIP buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris pH 8.0, 167 mM NaCl, protease inhibitors (Roche), 1 mM PMSF) precleared with salmon sperm DNA/protein A agarose slurry (Upstate Biotech) and immune precipitated with or without antibody (anti-A-myb, anti-B-myb, anti-c-myb, Santa Cruz) overnight at 41C with rotation. Immune complexes were collected with salmon sperm DNA/protein A agarose slurry (Upstate Biotech) for l h with rotation at 41C. The salmon sperm DNA/protein A agarose slurry (Upstate Biotech)/antibody/chromatin was washed with low salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris pH 8.0, 150 mM NaCl), high salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris pH 8.0, 500 mM NaCl), LiCl buffer (0.25 M LiCl, 1% Igepal, 1% sodium deoxycholate, 1 mM EDTA, 10 mM Tris pH8.0) and TE (10 mM Tris pH8.0, 1 mM EDTA), all containing protease inhibitors (Roche) and 1 mM PMSF. Bound material was eluted with 1% SDS, 0.1 M NaHCO 3 at room temperature for 15 min with rotation. Formaldehyde crosslinks were reversed with 0.3 M NaCl at 651C for 4 h. The DNA was precipitated at À201C, pelleted, resuspended in 10 mM EDTA, 40 mM Tris pH 6.5 and treated with 200 mg/ml proteinase K for 2 h at 451C. DNA was then purified using QiaQuick columns (Qiagen). ChIP reactions were done at least twice for each primer set using two different preparations of FDCP-Mix clone A4 cells. Linearity of PCRs was confirmed by comparing samples taken at 15, 20, 25 and 30 cycles. Data shown are for 25 cycles. Details of primers and conditions used for RT-PCR are available on request.
Flow cytometry
Thymocytes were purified from 6-week-old MEnT mice or WT littermates by standard methods (Coligan et al., 1991) , and stained with 58-6.7-APC for CD8a, GK1.5-PE for CD4 and OX-79 with a goat anti-rat Ig-FITC second layer for CD53 (BD Biosciences). Flow cytometric analysis used a Becton Dickinson FacsCalibur and CellQuest software.
Preparation of T-cell cDNA
Resting WT or MEnT CD4 þ splenocytes were isolated by negative depletion on LD columns using streptavidin microbeads (Miltenyi Biotech) and a cocktail of biotinylated antibodies (anti-CD8a, -B220, -GR1b, -CD11b, -CD11c, -TER119 and -Iab; BD Biosciences) at a dilution of 1 : 100 according to the manufacturer's instructions. Successful purification was confirmed by FACS analysis. Purified CD4 þ cells were activated in vitro by plating at a concentration of 1 Â 10 6 cells/ml in activation media (RPMI-1640 containing 10% FCS, 50 mM b-mercaptoethanol, nonessential amino acids, 0.1% penicillin/streptomycin and anti-CD28 antibody (37.51-10 mg/ ml)) in a 12-well plate precoated with anti-CD3 antibody (2C11 -20 mg/ml) for 3 h at 371C. Cells were incubated for 48 h at 371C in a humidified incubator containing 5% CO 2 and activated CD25 þ cells were purified by positive selection on an LS column using anti-PE microbeads (Miltenyi Biotech) and anti-CD25-PE-conjugated antibody (BD Biosciences) according to the manufacturer's instructions. Successful isolation of WT or MEnT CD4 þ CD25 þ cells was confirmed by FACS analysis. Total RNA was extracted from WT or MEnT CD4 þ CD25 þ cells using an RNeasy s Mini kit (Qiagen) and used as a template to synthesise cDNA using a Superscript II s kit (Invitrogen) according to the manufacturer's instructions. cDNA was quantitated and checked for purity by spectrophotometry at 260/280 nm and RT-PCR with actin primers.
